Anticancer research · 2003
A preparatory regimen of total body irradiation, busulphan and melphalan for allogeneic bone marrow transplantation in childhood high-risk leukemia and lymphoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yoshihara Takao, Naya Mayumi, Tsunamoto Kentaro, Hojo Makoto, Hibi Shigeyoshi, Morimoto Akira, Todo Shinjiro, Imashuku Shinsaku
Аннотация
The therapeutic results of allogeneic bone marrow transplantation (BMT), following a conditioning regimen of total body irradiation and busulphan and melphalan administration, were evaluated in 20 pediatric patients with high-risk leukemia or lymphoma. Twelve patients received BMT from HLA-matched related (MR) donors while eight received transplants from mismatched related or unrelated (MisR/UR) donors. The post-BMT five-year survival rates were much better for patients in the MR donor group (p = 0.0008). The outcomes of patients in the MisR/UR donor group were significantly worse. This was not due to disease recurrence, but to a high incidence of fatal post-transplant infections (p = 0.004). Nine out of twelve patients who received transplants from MR donors have remained in complete remission for a median of 57 (range 27-78) months. These results suggest that this conditioning regimen has a significant anti-neoplastic benefit useful for the preparation of pediatric patients receiving transplants from MR donors; however, refinement is essential before it can be used in patients receiving transplants from MisR/UR donors.
Предметные рубрики MeSH
AdolescentAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBusulfanChildChild, PreschoolFemaleHLA AntigensHumansInfantLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinLymphoma, T-CellMaleMelphalanPrecursor Cell Lymphoblastic Leukemia-LymphomaRisk FactorsTransplantation ConditioningTransplantation, HomologousTreatment OutcomeWhole-Body Irradiation